Ocular Hypertension-Pipeline Review H2 2017

ReportsWeb.com has announced the addition of the “Ocular Hypertension-Pipeline Review H2 2017” this report provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 7, 14, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

For more information about this report at http://www.reportsweb.com/ocular-hypertension-pipeline-review-h2-2017

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
-The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Request a sample copy at http://www.reportsweb.com/inquiry&RW00011022667/sample

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Company profiles

Aerie Pharmaceuticals Inc
Alcon Laboratories Inc
Allergan Plc
Bausch & Lomb Inc
Can-Fite BioPharma Ltd
D. Western Therapeutics Institute Inc
F. Hoffmann-La Roche Ltd
Ironwood Pharmaceuticals Inc
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Neurim Pharmaceuticals Ltd
NicOx SA
Ocular Therapeutix Inc
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU

Ask for Discount at http://www.reportsweb.com/inquiry&RW00011022667/discount

List of Tables

Number of Products under Development for Ocular Hypertension, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ocular Hypertension-Pipeline by Aerie Pharmaceuticals Inc, H2 2017
Ocular Hypertension-Pipeline by Alcon Laboratories Inc, H2 2017
Ocular Hypertension-Pipeline by Allergan Plc, H2 2017
Ocular Hypertension-Pipeline by Bausch & Lomb Inc, H2 2017
Ocular Hypertension-Pipeline by Can-Fite BioPharma Ltd, H2 2017
Ocular Hypertension-Pipeline by D. Western Therapeutics Institute Inc, H2 2017
Ocular Hypertension-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Ocular Hypertension-Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
Ocular Hypertension-Pipeline by Laboratoires Thea SA, H2 2017
Ocular Hypertension-Pipeline by Laboratorios Sophia SA de CV, H2 2017
Ocular Hypertension-Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Ocular Hypertension-Pipeline by NicOx SA, H2 2017
Ocular Hypertension-Pipeline by Ocular Therapeutix Inc, H2 2017
Ocular Hypertension-Pipeline by Santen Pharmaceutical Co Ltd, H2 2017
Ocular Hypertension-Pipeline by Senju Pharmaceutical Co Ltd, H2 2017
Ocular Hypertension-Pipeline by Shire Plc, H2 2017
Ocular Hypertension-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Purchase Complete Report at http://www.reportsweb.com/buy&RW00011022667/buy/2000

Contact Us:                 
Call: +1-646-491-9876
Email: sales@reportsweb.com

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

505, 6th floor, Amanora Township,
Amanora Chambers, East Block,
Kharadi Road, Hadapsar, Pune-411028

This release was published on openPR.